

Resource Summary Report

Generated by [dkNET](#) on Aug 30, 2026

MDM2 (SMP14)

RRID:AB_627920

Type: Antibody

Proper Citation

Santa Cruz Biotechnology Cat# sc-965, RRID:AB_627920

Antibody Information

URL: http://antibodyregistry.org/AB_627920

Proper Citation: Santa Cruz Biotechnology Cat# sc-965, RRID:AB_627920

Target Antigen: detection of MDM2, MDM2 p60 cleavage product and p53-MDM2 complexes

Host Organism: mouse

Clonality: monoclonal

Comments: Used By NYUIHC-1282

Info: Independent validation by the NYU Lagone was performed for: IHC. This antibody was found to have the following characteristics: Functional in human:FALSE, NonFunctional in human:FALSE, Functional in animal:FALSE, NonFunctional in animal:FALSE

Antibody Name: MDM2 (SMP14)

Description: This monoclonal targets detection of MDM2, MDM2 p60 cleavage product and p53-MDM2 complexes

Target Organism: rat, mouse, human

Clone ID: [SMP14]

Antibody ID: AB_627920

Vendor: Santa Cruz Biotechnology

Catalog Number: sc-965

Record Creation Time: 20250819T215204+0000

Record Last Update: 20250820T002112+0000

Ratings and Alerts

- Independent validation by the NYU Langone was performed for: IHC. This antibody was found to have the following characteristics: Functional in human:FALSE, NonFunctional in human:FALSE, Functional in animal:FALSE, NonFunctional in animal:FALSE - NYU Langone's Center for Biospecimen Research and Development <https://med.nyu.edu/research/scientific-cores-shared-resources/center-biospecimen-research-development>

No alerts have been found for MDM2 (SMP14).

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 38 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Sandoval TA, et al. (2026) Chemoradiation Reprograms Tumor Cells and the Immune Microenvironment in Cervical Cancer. *Cancer research*, 86(7), 1639.

Chua AJ, et al. (2026) Delivery of ATSP-7041 by Minimally Invasive Nasal Depot (MIND) to Target Diffuse Intrinsic Pontine Glioma. *Molecular cancer therapeutics*, 25(6), 992.

van der Laan L, et al. (2026) Generation of two human induced pluripotent stem cell lines (iPSC) from patients with Hao-Fountain Syndrome. *Stem cell research*, 92, 103934.

van der Laan L, et al. (2026) Generation of a human induced pluripotent stem cell line (iPSC) from a patient with Clark-Baraitser Syndrome. *Stem cell research*, 94, 104003.

Zhang D, et al. (2025) FLT3L-based drug conjugate effectively targets chemoresistant leukemia stem cells in acute myeloid leukemia. *Cell reports. Medicine*, 102365.

Mani R, et al. (2025) TP53 upregulation via aurora kinase inhibition overcomes primary failure to venetoclax in BCL2-rearranged lymphomas. *iScience*, 28(6), 112584.

Cordova RA, et al. (2024) Coordination between the eIF2 kinase GCN2 and p53 signaling supports purine metabolism and the progression of prostate cancer. *Science signaling*, 17(864), eadp1375.

Hsieh FS, et al. (2024) Plausible, robust biological oscillations through allelic buffering. *Cell systems*, 15(11), 1018.

Zong Z, et al. (2024) Alanyl-tRNA synthetase, AARS1, is a lactate sensor and lactyltransferase that lactylates p53 and contributes to tumorigenesis. *Cell*, 187(10), 2375.

Weinstein HNW, et al. (2024) RPL22 is a tumor suppressor in MSI-high cancers and a splicing regulator of MDM4. *Cell reports*, 43(8), 114622.

Hu H, et al. (2023) The RNA binding protein RALY suppresses p53 activity and promotes lung tumorigenesis. *Cell reports*, 42(4), 112288.

Wang X, et al. (2023) Targeting KRAS-mutant stomach/colorectal tumors by disrupting the ERK2-p53 complex. *Cell reports*, 42(1), 111972.

Mansky RH, et al. (2023) Tumor suppressor p53 regulates heat shock factor 1 protein degradation in Huntington's disease. *Cell reports*, 42(3), 112198.

Szwarc MM, et al. (2023) FAM193A is a positive regulator of p53 activity. *Cell reports*, 42(3), 112230.

Zhang L, et al. (2023) A p53/LINC00324 positive feedback loop suppresses tumor growth by counteracting SET-mediated transcriptional repression. *Cell reports*, 42(8), 112833.

Wu Z, et al. (2023) Coupled deglycosylation-ubiquitination cascade in regulating PD-1 degradation by MDM2. *Cell reports*, 42(7), 112693.

Granieri L, et al. (2022) Targeting the USP7/RRM2 axis drives senescence and sensitizes melanoma cells to HDAC/LSD1 inhibitors. *Cell reports*, 40(12), 111396.

Pranzini E, et al. (2022) SHMT2-mediated mitochondrial serine metabolism drives 5-FU resistance by fueling nucleotide biosynthesis. *Cell reports*, 40(7), 111233.

Rodriguez-Ramirez C, et al. (2022) p53 Inhibits Bmi-1-driven Self-Renewal and Defines Salivary Gland Cancer Stemness. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 28(21), 4757.

Zampetidis CP, et al. (2021) A recurrent chromosomal inversion suffices for driving escape from oncogene-induced senescence via subTAD reorganization. *Molecular cell*, 81(23), 4907.